• Profile
Close

Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV

New England Journal of Medicine Jul 28, 2021

Paton NI, Musaazi J, Kityo C, et al. - For second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection, dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended by the World Health Organization. In view of the limited evidence for the efficacy of this regimen when NRTIs are predicted to have no activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine, researchers herein conducted a two-by-two factorial, open-label, noninferiority trial. They randomized patients in whom first-line therapy was failing (HIV-1 viral load, ≥ 1,000 copies per milliliter), to receive dolutegravir or ritonavir-boosted darunavir and to receive tenofovir or zidovudine; all patients were administered lamivudine. Findings support the effectiveness of dolutegravir in combination with NRTIs in managing patients with HIV-1 infection, including those with extensive NRTI resistance in whom no NRTIs were predicted to have activity. They indicated noninferiority of tenofovir to zidovudine as second-line therapy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay